ArticleAlimentary pharmacology & therapeutics2018
Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Article in Alimentary pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC medicine · 2024Pooled it
- Trial
- Observational
- Unique genetic variants of lean nonalcoholic fatty liver disease: a retrospective cohort study.BMC endocrine disorders · 2023Article
- The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies.Gastro hep advances · 2022Review
- [Comparative study of clinicopathological features, and risk factors of advanced fibrosis between genders with non-alcoholic fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice.Hepatology communications · 2020Article
- Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease.Clinical liver disease · 2020Review
- Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.Cellular and molecular life sciences : CMLS · 2020Review
- Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease.Cancer medicine · 2020Article
- Artificial Intelligence Pipeline to Bridge the Gap between Bench Researchers and Clinical Researchers in Precision Medicine.Med one · 2020Article
- Review
- Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?World journal of gastroenterology · 2019Review
- Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2019Article
- Identifying and Treating Nonalcoholic Fatty Liver Disease.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2019Article
- Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients.Journal of clinical medicine · 2018Article
- Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.Digestive diseases and sciences · 2018Article
- The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD).Non-coding RNA · 2018Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWith its increasing incidence, nonalcoholic fatty liver disease (NAFLD) is of particular concern in the Veterans Health Administration (VHA).
aimsTo evaluate risk factors for advanced fibrosis in biopsy-proven NAFLD in the VHA, to identify patients at risk for adverse outcomes.
methodsIn randomly selected cases from VHA databases (2005-2015), we performed a retrospective case-control study in adults with biopsy-defined NAFLD or normal liver.
resultsOf 2091 patients reviewed, 399 met inclusion criteria. Normal controls (n = 65) had normal liver function. The four NAFLD cohorts included: NAFL steatosis (n = 76), nonalcoholic steatohepatitis (NASH) without fibrosis (n = 68), NAFLD/NASH stage 1-3 fibrosis (n = 82), and NAFLD/NASH cirrhosis (n = 70). NAFLD with hepatocellular carcinoma (HCC) was separately identified (n = 38). Most patients were older White men. NAFLD patients with any fibrosis were on average severely obese (BMI>35 kg/m
conclusionsIn the VHA, diabetes and severe obesity increased risk for advanced fibrosis in NAFLD. Of these patients, only a small proportion (~20%) had enrolled in diet/exercise programs or had bariatric surgery (~2%). These results suggest that providers should focus/tailor interventions to improve outcomes, particularly in those with diabetes and severe obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.